老年人流感疫苗抗体应答能否全年持续?系统综述与Meta分析
该系统综述与Meta分析检索了报告老年人接种灭活三价季节性流感疫苗后180-360天血凝抑制(HI)抗体滴度的研究,共16项研究2565名受试者纳入分析。贝叶斯模型显示血清保护比例从接种前41-51%升至血清转换时75-78%,至第360天所有血清型均降至60%以下;Meta分析未发现第360天与接种前血清保护比例或log2GMT有显著差异。
要点
- 老年人接种流感疫苗后HI抗体应答不能可靠地全年持续。
- 血清保护比例从接种前41-51%升至血清转换时75-78%,第360天所有血清型降至60%以下。
- 第360天与接种前血清保护比例差异为0(95%CI -0.11至0.11),log2GMT差异为0.30(95%CI -0.02至0.63),均无显著差异。
核心结论
- 本综述发现一致证据表明老年人接种流感疫苗后HI抗体应答不能可靠地全年持续。
- 在需要全年保护的区域,替代接种策略可能提供临床获益。
研究设计与样本
- 系统综述与Meta分析,方案注册于PROSPERO(CRD42015023847)。
- 检索电子数据库,纳入报告65岁及以上成人接种灭活三价季节性流感疫苗后180-360天血凝抑制(HI)滴度的研究。
- 共检索到2864篇文章,19篇符合纳入/排除标准,其中16项研究含可分析数据,共2565名受试者。
- 采用贝叶斯模型描述从接种前至第360天的滴度轨迹,Meta分析采用随机效应模型汇总。
主要发现
- 贝叶斯模型中,血清保护比例从接种前41-51%升至血清转换时75-78%。
- 至第360天,所有血清型血清保护比例降至60%以下:A/H1为42%(95%CI 38-46),A/H3为59%(95%CI 54-63),B为47%(95%CI 42-52)。
- 贝叶斯模型GMT轨迹显示相似模式,至第360天滴度与接种前水平相近。
- Meta分析中,第360天与接种前相比,血清保护比例差异为0(95%CI -0.11至0.11),log2GMT差异为0.30(95%CI -0.02至0.63),均无显著差异。
关键数值与推荐
- 血清保护定义为HI滴度≥1:40。
- 血清转换评估时间点为第21-42天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据质量因显著的研究对象脱落而限于中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The influenza vaccine is less immunogenic in older than younger adults, and the duration of protection is unclear. Determining if protection persists beyond a typical seasonal epidemic is important for climates where influenza virus activity is year-round. METHODS: A systematic review protocol was developed and registered with PROSPERO [CRD42015023847]. Electronic databases were searched systematically for studies reporting haemagglutination-inhibition (HI) titres 180-360days following vaccination with inactivated trivalent seasonal influenza vaccine, in adults aged ⩾65years. Geometric mean titre (GMT) and seroprotection (HI titre ⩾1:40) at each time point was extracted. A Bayesian model was developed of titre trajectories from pre-vaccination to Day 360. In the meta-analysis, studies were aggregated using a random-effects model to compare pre-vaccination with post-vaccination HI titres at Day 21-42 ('seroconversion'), Day 180 and Day 360. Potential sources of bias were systematically assessed, and heterogeneity explored. RESULTS: 2864 articles were identified in the literature search, of which nineteen met study inclusion/exclusion criteria. Sixteen studies contained analysable data from 2565 subjects. In the Bayesian model, the proportion of subjects seroprotected increased from 41-51% pre-vaccination to 75-78% at seroconversion. Seroprotection subsequently fell below 60% for all serotypes by Day 360: A/H1 42% (95% CI 38-46), A/H3 59% (54-63), B 47% (42-52). The Bayesian model of GMT trajectories revealed a similar pattern. By Day 360, titres were similar to pre-vaccination levels. In the meta-analysis, no significant difference in proportion of subjects seroprotected, 0 (-0.11, 0.11) or in log2GMT 0.30 (-0.02, 0.63) was identified by Day 360 compared with pre-vaccination. The quality of this evidence was limited to moderate on account of significant participant dropout. CONCLUSIONS: The review found consistent evidence that HI antibody responses following influenza vaccination do not reliably persist year-round in older adults. Alternative vaccination strategies could provide clinical benefits in regions where year-round protection is important.
引用
- Young B, Zhao X, Cook AR, et al. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine. 2016. PMID: 27939013. doi:10.1016/j.vaccine.2016.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。